A groundbreaking study reveals semaglutide, already known for weight loss and diabetes treatment, is effective for fatty liver disease, benefiting two-thirds of participants in a recent trial. This could revolutionize treatment options!
The U.S. Department of Health and Human Services is on a bold mission to develop a universal flu vaccine within four years, a project that could revolutionize how we combat influenza and prepare for future pandemics. Funded by $500 million, this initiative aims for FDA approval by 2029, with clinical trials starting soon. Experts weigh in on the challenges and potential of this ambitious project.
A recent survey reveals that older Americans are increasingly proactive about Alzheimer's, with 79% wanting to know if they have the disease before symptoms arise. Many would opt for a blood test and are open to new drug treatments.
A groundbreaking urine test for prostate cancer has shown remarkable accuracy, outperforming traditional blood tests. Set to enter clinical trials, this innovation may make routine screenings a reality, potentially saving thousands of lives.
A groundbreaking study reveals that immunotherapy drug dostarlimab has led to remarkable tumor disappearance in cancer patients, offering a new hope for those battling solid tumors.
Pfizer Inc. has decided to stop the development of its obesity pill, danuglipron, after safety concerns emerged from a clinical trial. This move comes as competition heats up with Novo Nordisk and Eli Lilly's successful weight-loss treatments.
Recent research suggests that Ozempic and similar GLP-1 drugs may lower the risk of dementia in those with type 2 diabetes. Discover how these drugs are being tested for dementia prevention!
A new clinical trial reveals that fasting every other day can lead to greater weight loss compared to traditional calorie cutting. Discover how this method may help you shed pounds more effectively!
Novo Nordisk's diabetes pill Rybelsus has shown significant cardiovascular benefits, reducing the risk of heart-related issues by 14%. This could offer a new, convenient treatment option for many patients.
Eli Lilly is set to unveil results from trials of orforglipron, its groundbreaking once-daily obesity pill, potentially revolutionizing weight loss treatment by offering a needle-free alternative. Analysts predict it could capture a significant share of the $150 billion GLP-1 market.
